MCID: SCH011
MIFTS: 36

Schizotypal Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Schizotypal Personality Disorder

MalaCards integrated aliases for Schizotypal Personality Disorder:

Name: Schizotypal Personality Disorder 12 76 55 44 15 73
Schizotypal Personality 55

Classifications:



External Ids:

Disease Ontology 12 DOID:10646
ICD10 33 F21
ICD9CM 35 301.22
MeSH 44 D012569
NCIt 50 C92632
SNOMED-CT 68 231486008 31027006
UMLS 73 C0036363

Summaries for Schizotypal Personality Disorder

Disease Ontology : 12 A personality disorder that involves a need for social isolation, anxiety in social situations, odd behavior and thinking, and often unconventional beliefs.

MalaCards based summary : Schizotypal Personality Disorder, also known as schizotypal personality, is related to schizoaffective disorder and schizophrenia. An important gene associated with Schizotypal Personality Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways is Androgen receptor signaling pathway. The drugs Guanfacine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and eye, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Schizotypal personality disorder (STPD) or schizotypal disorder is a mental disorder characterized by... more...

Related Diseases for Schizotypal Personality Disorder

Diseases related to Schizotypal Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 schizoaffective disorder 29.4 COMT SULT4A1
2 schizophrenia 28.9 CACNA1C COMT PSAT1 SULT4A1
3 disease of mental health 28.9 COMT EP300
4 personality disorder 11.0
5 obsessive-compulsive disorder 10.3
6 borderline personality disorder 10.1
7 anorexia nervosa 10.0
8 cerebritis 10.0
9 autism 9.9
10 major depressive disorder 9.9
11 avoidant personality disorder 9.9
12 childhood-onset schizophrenia 9.9
13 depression 9.9
14 mood disorder 9.5 CACNA1C COMT

Graphical network of the top 20 diseases related to Schizotypal Personality Disorder:



Diseases related to Schizotypal Personality Disorder

Symptoms & Phenotypes for Schizotypal Personality Disorder

GenomeRNAi Phenotypes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.44 EP300
2 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.44 EP300
3 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.44 SULT4A1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.44 EP300 SULT4A1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.44 EP300
6 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.44 EP300
7 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.44 SULT4A1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.44 EP300
9 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.44 SULT4A1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.44 EP300
11 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.44 EP300
12 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.44 EP300

MGI Mouse Phenotypes related to Schizotypal Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.02 CACNA1C COMT EP300 FLNA PSAT1

Drugs & Therapeutics for Schizotypal Personality Disorder

Drugs for Schizotypal Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
2 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
3 Adrenergic Agents Phase 4,Phase 2
4 Adrenergic Agonists Phase 4,Phase 2
5 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2
6 Adrenergic alpha-Agonists Phase 4,Phase 2
7 Antihypertensive Agents Phase 4,Phase 2
8
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
9 Protective Agents Phase 3,Phase 2
10 Antidotes Phase 3
11 Anti-Infective Agents Phase 3
12 Antioxidants Phase 3
13 Antiviral Agents Phase 3
14 Expectorants Phase 3
15 N-monoacetylcystine Phase 3
16 Respiratory System Agents Phase 3
17
Dopamine Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
18
Risperidone Approved, Investigational Phase 1, Phase 2,Not Applicable 106266-06-2 5073
19 Dihydrexidine Investigational Phase 2 123039-93-0
20 Dopamine Agents Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Dopamine agonists Phase 2,Not Applicable,Early Phase 1
22 Antipsychotic Agents Phase 1, Phase 2,Not Applicable
23 Central Nervous System Depressants Phase 1, Phase 2,Not Applicable
24 Dopamine Antagonists Phase 1, Phase 2,Not Applicable
25 Psychotropic Drugs Phase 1, Phase 2,Not Applicable
26 Serotonin Agents Phase 1, Phase 2,Not Applicable
27 Serotonin Antagonists Phase 1, Phase 2,Not Applicable
28 Tranquilizing Agents Phase 1, Phase 2,Not Applicable
29 Autonomic Agents Phase 2
30 Peripheral Nervous System Agents Phase 2
31
Serotonin Investigational, Nutraceutical Phase 1, Phase 2,Not Applicable 50-67-9 5202
32
Oxytocin Approved, Vet_approved Phase 1 50-56-6 439302 53477758
33 Oxytocics Phase 1
34
Benserazide Approved, Investigational Early Phase 1 322-35-0
35
Levodopa Approved Early Phase 1 59-92-7 6047
36
Sertraline Approved Not Applicable 79617-96-2 68617
37
Adenosine Approved, Investigational 58-61-7 60961
38
Aripiprazole Approved, Investigational Not Applicable 129722-12-9 60795
39 Antiparkinson Agents Early Phase 1
40 Benserazide, levodopa drug combination Early Phase 1
41 Dihydroxyphenylalanine Early Phase 1
42 Antidepressive Agents Not Applicable
43 Neurotransmitter Uptake Inhibitors Not Applicable
44 Serotonin Uptake Inhibitors Not Applicable
45 interferons

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Pharmacology of Cognition in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
2 "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients" Recruiting NCT03149107 Phase 3 N-Acetylcysteine;Placebo
3 Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder Unknown status NCT01466205 Phase 2 DAR-0100A;Placebo
4 Schizotypal Personality Disorder Risperidone Completed NCT02535156 Phase 1, Phase 2 Risperidone;Placebo
5 A D1 Agonist For Working Memory Completed NCT02507206 Phase 2 DAR 0-100A;Placebo
6 CRT-Guanfacine for SPD Completed NCT02524899 Phase 2 Guanfacine;Placebo
7 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
8 Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder Unknown status NCT00252044 Not Applicable Pergolide
9 Health Promotion on Young Adults With High Risk Disability for Mental Health Unknown status NCT01740167 Not Applicable
10 Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder Completed NCT00158028 Not Applicable Risperidone;Placebo
11 Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission Completed NCT03333369 Early Phase 1 200 mg levodopa/50 mg benserazide;Dextrose
12 A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions Completed NCT00155519
13 Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis Completed NCT01619319 Not Applicable
14 Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms Completed NCT00169988 Not Applicable risperidone;sertraline-primary
15 Extended Specialized Assertive Intervention for First Episode Psychosis Completed NCT00914238 Not Applicable
16 Psychosis: Early Detection, Intervention and Prevention Completed NCT01597141 Not Applicable
17 Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study Completed NCT01269710
18 Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life Completed NCT02943330
19 Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample Recruiting NCT02800681
20 Neurofeedback Training for High Risk Psychosis Recruiting NCT03447548 Not Applicable
21 Semantic and Syntactic Computerized Analysis of Free Speech Recruiting NCT03525054
22 Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis Active, not recruiting NCT00157313 Not Applicable
23 Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology Not yet recruiting NCT03355781
24 Aripiprazole Treatment of the Prodrome Terminated NCT00169949 Not Applicable aripiprazole

Search NIH Clinical Center for Schizotypal Personality Disorder

Cochrane evidence based reviews: schizotypal personality disorder

Genetic Tests for Schizotypal Personality Disorder

Anatomical Context for Schizotypal Personality Disorder

MalaCards organs/tissues related to Schizotypal Personality Disorder:

41
Testes, Brain, Eye, Caudate Nucleus, Temporal Lobe, Pituitary, Cortex

Publications for Schizotypal Personality Disorder

Articles related to Schizotypal Personality Disorder:

(show top 50) (show all 193)
# Title Authors Year
1
Frontal and temporal cortical volume, white matter tract integrity, and hemispheric asymmetry in schizotypal personality disorder. ( 29454512 )
2018
2
Enhanced mental imagery and intact perceptual organization in schizotypal personality disorder. ( 29131991 )
2018
3
Reduced functional connectivity between bilateral precuneus and contralateral parahippocampus in schizotypal personality disorder. ( 28152990 )
2017
4
Comparing Facial Emotional Recognition in Patients with Borderline Personality Disorder and Patients with Schizotypal Personality Disorder with a Normal Group. ( 28659980 )
2017
5
Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. ( 28347257 )
2017
6
Supervoxel-based statistical analysis of diffusion tensor imaging in schizotypal personality disorder. ( 28712990 )
2017
7
Dissociation of Brain Activation in Autism and Schizotypal Personality Disorder During Social Judgments. ( 29088456 )
2017
8
Biological Motion Perception, Brain Responses, and Schizotypal Personality Disorder. ( 26790398 )
2016
9
Characterization of the Fiber Connectivity Profile of the Cerebral Cortex in Schizotypal Personality Disorder: A Pilot Study. ( 27303358 )
2016
10
Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. ( 27330977 )
2016
11
Decreased fractional anisotropy values in two clusters of white matter in patients with schizotypal personality disorder: A DTI study. ( 27178397 )
2016
12
Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia. ( 25482574 )
2015
13
The melbourne assessment of Schizotypy in kids: a useful measure of childhood schizotypal personality disorder. ( 25629050 )
2015
14
Screening schizotypal personality disorder for detection of clinical high risk of psychosis in Chinese mental health services. ( 26165958 )
2015
15
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. ( 25074637 )
2014
16
Visual-spatial working memory performance and temporal gray matter volume predict schizotypal personality disorder group membership. ( 24398009 )
2014
17
White Matter Abnormalities in Schizophrenia and Schizotypal Personality Disorder. ( 24962608 )
2014
18
Altered default mode network functional connectivity in schizotypal personality disorder. ( 25458858 )
2014
19
Schizotypal personality disorder: a current review. ( 24828284 )
2014
20
Openness to experience, intellect, schizotypal personality disorder, and psychoticism: resolving the controversy. ( 24511900 )
2014
21
Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [(11)C]NNC112. ( 24781514 )
2014
22
DSM-IV schizotypal personality disorder: a taxometric analysis among individuals with and without substance use disorders in the general population. ( 26322122 )
2014
23
Empathic accuracy and cognition in schizotypal personality disorder. ( 23810511 )
2013
24
Globally and locally reduced MRI gray matter volumes in neuroleptic-naive men with schizotypal personality disorder: association with negative symptoms. ( 23389420 )
2013
25
CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals. ( 22985546 )
2013
26
Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. ( 24200416 )
2013
27
Prodromal and autistic symptoms in schizotypal personality disorder and 22q11.2 deletion syndrome. ( 22686870 )
2013
28
Larger putamen size in antipsychotic-naA^ve individuals with schizotypal personality disorder. ( 23187070 )
2013
29
Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. ( 23375943 )
2013
30
Semantic processing impairment in individuals with schizotypal personality disorder features: a preliminary event-related potential study. ( 22960083 )
2013
31
Schizotypal personality disorder. ( 22928856 )
2013
32
Developmental trajectories of schizotypal personality disorder-like behavioural manifestations: a two-year longitudinal prospective study of college students. ( 24289659 )
2013
33
Neuroimaging findings in schizotypal personality disorder: a systematic review. ( 23220094 )
2013
34
Does a latent class underlie schizotypal personality disorder? Implications for schizophrenia. ( 23713503 )
2013
35
Working memory in schizotypal personality disorder: fMRI activation and deactivation differences. ( 24161536 )
2013
36
Prosodic abnormalities in schizotypal personality disorder. ( 23068317 )
2012
37
Auditory steady state response in the schizophrenia, first-degree relatives, and schizotypal personality disorder. ( 22285558 )
2012
38
A review of structural MRI and diffusion tensor imaging in schizotypal personality disorder. ( 22006127 )
2012
39
Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. ( 22325079 )
2012
40
Anterior limb of the internal capsule in schizotypal personality disorder: fiber-tract counting, volume, and anisotropy. ( 22995934 )
2012
41
Some suggestions for the DSM-5 schizotypal personality disorder construct. ( 21741634 )
2012
42
Cingulate and temporal lobe fractional anisotropy in schizotypal personality disorder. ( 21223999 )
2011
43
The differential effects of child abuse and posttraumatic stress disorder on schizotypal personality disorder. ( 21683181 )
2011
44
A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression. ( 20955740 )
2011
45
Prodromal symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal personality disorder. ( 21507614 )
2011
46
Dorso- and ventro-lateral prefrontal volume and spatial working memory in schizotypal personality disorder. ( 21115066 )
2011
47
Deficient visual sensitivity in schizotypal personality disorder. ( 20541911 )
2011
48
Facial emotion recognition and facial affect display in schizotypal personality disorder. ( 21640557 )
2011
49
Evidence of reduced selective attention in schizotypal personality disorder. ( 21526445 )
2011
50
Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. ( 20130535 )
2010

Variations for Schizotypal Personality Disorder

Expression for Schizotypal Personality Disorder

Search GEO for disease gene expression data for Schizotypal Personality Disorder.

Pathways for Schizotypal Personality Disorder

Pathways related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.58 EP300 FLNA

GO Terms for Schizotypal Personality Disorder

Cellular components related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.1 CACNA1C COMT EP300 FLNA PSAT1 SULT4A1
2 Z disc GO:0030018 8.96 CACNA1C FLNA

Biological processes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to estrogen GO:0043627 8.62 COMT EP300

Molecular functions related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 8.92 COMT EP300 PSAT1 SULT4A1

Sources for Schizotypal Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....